(Q3)Feb 29, 2024 | (Q2)Nov 30, 2023 | (Q1)Aug 31, 2023 | (FY)May 31, 2023 | (Q4)May 31, 2023 | (Q3)Feb 28, 2023 | (Q2)Nov 30, 2022 | (Q1)Aug 31, 2022 | (FY)May 31, 2022 | (Q4)May 31, 2021 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | -199.82%-284.06K | -443.43%-116.88K | -2,071.69%-727.17K | -103.64%-575.3K | -481.11K | -94.74K | 34.03K | -33.48K | -282.51K | 0 |
Net income from continuing operations | -320.67%-327.34K | -614.86%-511.54K | -1,517.07%-769.45K | -37.33%-593.48K | ---396.52K | ---77.82K | ---71.56K | ---47.58K | ---432.15K | --0 |
Remuneration paid in stock | --135.65K | --141.38K | --105.71K | 22.09%90.48K | --90.48K | --0 | --0 | --0 | --74.11K | ---- |
Change In working capital | -445.65%-92.37K | 139.86%253.27K | -549.89%-63.43K | -195.71%-72.3K | ---175.06K | ---16.93K | --105.59K | --14.1K | --75.54K | --0 |
-Change in receivables | 10,916.54%57.95K | -3,655.88%-51.08K | -1,306.88%-13.08K | -470.50%-17.85K | ---16.09K | --526 | ---1.36K | ---930 | ---3.13K | --0 |
-Change in prepaid assets | 1,609.22%35.35K | --59.49K | ---21.42K | ---134.68K | ---132.34K | ---2.34K | --0 | --0 | --0 | ---- |
-Change in payables and accrued expense | -1,128.57%-185.66K | 128.95%244.86K | -292.46%-28.93K | 1.99%80.23K | ---26.64K | ---15.11K | --106.95K | --15.03K | --78.67K | --0 |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | -199.82%-284.06K | -443.43%-116.88K | -2,071.69%-727.17K | -103.64%-575.3K | ---481.11K | ---94.74K | --34.03K | ---33.48K | ---282.51K | --0 |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | -196.69K | -935.10%-776.33K | -380.65K | -175K | -100K | 0 | -75K | 0 | 0 | |
Net PPE purchase and sale | ---196.69K | -935.10%-776.33K | ---380.65K | ---- | ---- | --0 | ---75K | --0 | ---- | ---- |
Net other investing changes | ---- | ---- | ---- | ---175K | ---- | ---- | ---- | ---- | ---- | ---- |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | ---196.69K | -935.10%-776.33K | ---380.65K | ---175K | ---100K | --0 | ---75K | --0 | --0 | ---- |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | -99.31%7.26K | 1.92M | 2.12M | 24.20%1.07M | 7.27K | 1.06M | 0 | 0 | 858.85K | 1 |
Net common stock issuance | --0 | --2.2M | --2.12M | 24.20%1.07M | --7.27K | --1.06M | --0 | --0 | --858.85K | --1 |
Proceeds from stock option exercised by employees | --7.26K | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
Net other financing activities | --0 | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | -99.31%7.26K | --1.92M | --2.12M | 24.20%1.07M | --7.27K | --1.06M | --0 | --0 | --858.85K | --1 |
Net cash flow | ||||||||||
Beginning cash position | 484.55%2.93M | 250.77%1.9M | 54.89%892.71K | 57,634,300.00%576.34K | --1.47M | --501.89K | --542.86K | --576.34K | --1 | --0 |
Current changes in cash | -149.08%-473.48K | 2,613.35%1.03M | 3,120.85%1.01M | -45.11%316.37K | ---573.84K | --964.66K | ---40.97K | ---33.48K | --576.34K | --1 |
End cash Position | 67.76%2.46M | 484.55%2.93M | 250.77%1.9M | 54.89%892.71K | --892.71K | --1.47M | --501.89K | --542.86K | --576.34K | --1 |
Free cash from | -407.42%-480.74K | -2,080.37%-893.21K | -3,208.50%-1.11M | -103.64%-575.3K | ---406.11K | ---94.74K | ---40.97K | ---33.48K | ---282.51K | --0 |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.